[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659996":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":16,"studyPopulation":17,"armGroups":11,"interventions":18,"overallOfficials":22,"centralContacts":26,"locations":31,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":11,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Quality of Life Questionnaire",null,"Through study completion; an average of 1 year",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","CROSS_SECTIONAL","1. To explore patterns and variability in QoL across individual instrument subscales (e.g., EORTC QLQ-C30 functional and symptom domains; HADS anxiety and depression subscales).\n2. To examine associations between QoL outcomes and clinical\u002Ftreatment-related variables, including time since surgery.\n3. To identify participant-reported survivorship needs, gaps in care, and potential targets for survivorship-focused interventions (e.g., development of a survivorship clinic), with particular emphasis on qualitative responses.","UT MD Anderson Cancer Center",[19],{"type":6,"name":20,"description":21,"armGroupLabels":11,"otherNames":11},"Questionnaire and Physical Exam","All questionnaires will be complete remotely through REDCap",[23],{"name":24,"affiliation":17,"role":25},"Yun Song, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":11,"email":30},"CONTACT","346-722-0041","YSong9@mdanderson.org",[32],{"facility":17,"status":11,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Houston","Texas","77030","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-95.36327,29.76328,{"lat":42,"lon":41},[45,46],{"name":24,"role":28,"phone":29,"phoneExt":11,"email":30},{"name":24,"role":25,"phone":11,"phoneExt":11,"email":11},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100659996","long-term-quality-of-life-and-symptom-assessment-among-recurrence-free-patients-who-underwent-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-100659996",false,"NCT07871760","Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","Inclusion Criteria:\n\n1. Males and females; age ≥18 years at the time of enrollment\n2. Underwent curative-intent CRS\u002FHIPEC at MD Anderson for gastrointestinal malignancies, including colorectal cancers, appendiceal cancers, and peritoneal mesothelioma between March 1, 2016, and June 30, 2025\n3. Had a complete cytoreduction with a completeness of cytoreduction score (CC) of 0 or 1\n4. Currently alive and at least 6 months disease-free post-CRS\u002FHIPEC, based on clinical documentation and follow-up imaging\n5. English-speaking\n6. Capable of completing an electronic survey (via REDCap)\n7. Provides informed consent by proceeding to survey commencement\n\nExclusion Criteria:\n\n* 1\\. Evidence of recurrent or active malignancy at time of chart review 2. Underwent CRS\u002FHIPEC for non-malignant conditions (e.g., multicystic mesothelioma, well-differentiated papillary mesothelioma) 3. Underwent palliative-intent surgery or had an incomplete cytoreduction (CC-2 or CC-3) 4. Did not receive HIPEC (CRS only) 5. Received HIPEC on a clinical trial 6. Significant cognitive impairment limiting ability to provide informed consent or complete the survey 7. Non-English-speaking (due to lack of validated translations for study instruments) 8. No valid contact information or no access to electronic communication (e.g., participant portal or email)","ALL","18 Years",{"count":58,"type":59},300,"ESTIMATED","OBSERVATIONAL","To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS\u002FHIPEC) at MD Anderson, with primary emphasis on overall (composite) QoL as measured by validated instruments.",[63,64,65,66,67],"Long Term","Quality of Life","Recurrence Free","Cytoreductive Surgery","Hyperthermic Intraperitoneal Chemotherapy","NOT_YET_RECRUITING","2026-10-08",{"date":71,"type":72},"2026-10-13","ACTUAL",{"date":74,"type":59},"2027-03-22",{"date":76,"type":59},"2028-12-31",{"name":5,"class":6},1]